eyestock logo

eyestock

ML

Mineralys Therapeutics IncNASDAQ MLYS

Последний отчетный период 30 сент., 2023

Обновлено 20 нояб., 2024

Последняя цена

Капитализация млрд. $

0.72

Micro

Биржа

XNAS - Nasdaq

Анализ акций MLYS

ML

Нет оценки

Количественный анализ Eyestock не покрывает акции Mineralys Therapeutics Inc.

Капитализация млрд. $

0.72

Дивидендная доходность

Оборот

39.057 млрд

Сайт компании

https://mineralystx.com/

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engages in developing medicines to target disease, driven by abnormally elevated aldosterone. The company is headquartered in Radnor, Pennsylvania. The company went IPO on 2023-02-10. The firm is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). The firm completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. The company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

Смотреть Секцию: Рейтинг